Related Experiment Video
Updated: Feb 27, 2026

Real-Time Monitoring of Human Glioma Cell Migration on Dorsal Root Ganglion Axon-Oligodendrocyte Co-Cultures
Published on: December 13, 2019
Regulation of Glioma Cells Migration by DYRK2
Yifen Shen1, Li Zhang1, Donglin Wang2
1Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu Province, People's Republic of China.
Abstract:
Dual-specificity tyrosine-regulated kinase 2 (DYRK2), a protein kinase that phosphorylates its substrates on serine/threonine, is expressed in numerous human tumors, but little is known about its role in the pathophysiology of glioma. In this study, we made an effort to explore the expression and function in human glioma. Western blot and immunohistochemistry analysis were performed to investigate the expression of DYRK2 protein in glioma tissues in 84 patients. Wound healing and transwell assay were carried out to determine the cell migration ability. We showed that the level of DYRK2 was significantly decreased in high-grade glioma tissues compared with low-grade tissues. In addition, the expression level of DYRK2 was positively correlated with glioma pathological grade and E-cadherin expression. Kaplane-Meier analysis revealed that low expression of DYRK2 was related to poor prognosis of glioma patients. Furthermore, wound healing and transwell assay revealed that DYRK2 could suppress cell migration and affect the expression levels of E-cadherin and vimentin through PI3K/AKT/GSK3β signaling pathway. Taken together, our results implied that DYRK2 could serve as a promising prognostic biomarker as well as a potential therapeutical target of glioma.
Insights
Dual-specificity tyrosine-regulated kinase 2 (DYRK2) expression decreases in high-grade gliomas, correlating with poor prognosis. DYRK2 suppresses glioma cell migration via the PI3K/AKT/GSK3β pathway, indicating its potential as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Dual-specificity tyrosine-regulated kinase 2 (DYRK2) is a protein kinase implicated in various cellular processes.
- Its role in glioma pathophysiology remains largely unexplored despite its presence in human tumors.
Purpose of the Study:
- To investigate the expression and functional role of DYRK2 in human glioma.
- To determine DYRK2's potential as a prognostic biomarker and therapeutic target in glioma.
Main Methods:
- Western blot and immunohistochemistry were used to analyze DYRK2 expression in 84 glioma patient tissues.
- Cell migration was assessed using wound healing and Transwell assays.
- The involvement of the PI3K/AKT/GSK3β signaling pathway was examined.
Main Results:
- DYRK2 expression was significantly lower in high-grade gliomas compared to low-grade tissues.
- Lower DYRK2 levels correlated with higher pathological grade, increased E-cadherin expression, and poorer patient prognosis.
- DYRK2 suppressed glioma cell migration and modulated E-cadherin and vimentin expression through the PI3K/AKT/GSK3β pathway.
Conclusions:
- DYRK2 expression is inversely correlated with glioma grade and patient prognosis.
- DYRK2 acts as a suppressor of glioma cell migration, potentially via the PI3K/AKT/GSK3β signaling pathway.
- DYRK2 represents a promising prognostic biomarker and a potential therapeutic target for glioma treatment.
Related Concept Videos
Cell Migration
Cell Migration
Cell Polarization by Rho Proteins
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Cytoskeletal Coordination in Cell Migration
Cancer Cell Migration through Invadopodia

